POINT RICHMOND, Calif., Feb. 29, 2012 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that Transcept management is scheduled to present at two investor conferences in March 2012.
Transcept management plans to present a general corporate overview at the:
Cowen Health Care Conference in Boston, Massachusetts on March 5, 2012, 4:50 p.m. ET; andRoth Conference in Laguna Niguel, California on March 14, 2012, 10:00 a.m. PT
A live audio webcast of each presentation will be available in the investor relations section of the Transcept website at www.transcept.com. An archive of the presentation will also be available in the investor section on the Transcept website for approximately 30 days following the event.About Transcept PharmaceuticalsTranscept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Intermezzo® (zolpidem tartrate) sublingual tablet C-IV is the first FDA approved Transcept product. Transcept and Purdue are parties to a collaboration agreement for the development and commercialization of Intermezzo in the United States. Transcept holds all commercialization and development rights to Intermezzo outside North America and has co-promotion rights to Intermezzo in the United States. As part of its product pipeline activities, Transcept is currently conducting a Phase 2 study of an investigational product, TO-2061, in patients with obsessive-compulsive disorder. For information about Intermezzo, please visit www.intermezzorx.com. For further information about Transcept, please visit www.transcept.com. Contact:Transcept Pharmaceuticals, Inc. Greg MannSr. Director, Corporate Communications(510) 215-3567 email@example.com SOURCE Transcept Pharmaceuticals, Inc.